Medicure completes enrollment in MEND-PNPO Phase 3 trial
- Medicure completed enrollment of 10 patients in its MEND-PNPO Phase 3 trial
- MC-1 holds FDA Orphan Drug, Rare Pediatric Disease, and Fast Track designations
- Company eligible for Priority Review Voucher upon NDA approval
- Baseline data presented at European Epilepsy Congress; further presentations scheduled
*this image is generated using AI for illustrative purposes only.
Medicure Inc. announced the completion of patient enrollment in its MEND-PNPO Phase 3 clinical trial. The pivotal study evaluated MC-1 for the treatment of Pyridox(am)ine 5'-Phosphate Oxidase (PNPO) deficiency.
The trial successfully enrolled 10 patients, meeting the company's enrollment objective. Patients continue to progress through treatment and follow-up periods, with several having already completed key study milestones. PNPO deficiency is an ultra-rare inherited neurometabolic disorder that causes severe seizures in newborns and infants. Without treatment, it can lead to significant developmental impairment, neurological dysfunction, and death.
Regulatory designations and potential incentives
The U.S. Food and Drug Administration (FDA) has granted Rare Pediatric Disease Designation, Orphan Drug Designation, and Fast Track Designation to MC-1 for this indication. The European Medicines Agency (EMA) has also granted Orphan Drug Designation. These designations aim to facilitate the development and review of a future New Drug Application (NDA).
Upon approval of an NDA, Medicure is eligible to receive a Priority Review Voucher from the FDA. This voucher can be redeemed or sold, providing a potential financial benefit alongside commercial revenue.
Clinical data presentation schedule
The company presented the study design and baseline data at the European Epilepsy Congress (EEC) in Athens earlier this year. Lead investigator Phillip Pearl, MD, Director of Epilepsy and Clinical Neurophysiology at Boston Children's Hospital, delivered the presentation. It outlined primary and secondary endpoints, the MC-1 dosing regimen, and baseline pyridoxal 5'-phosphate (P5P) levels.
The same data will be presented later this year at:
- Child Neurology Society (CNS) Annual Meeting in Montreal, Canada
- American Epilepsy Society (AES) Annual Meeting in Denver, Colorado
What the numbers show
The completion of enrollment marks a transition from recruitment to data collection for a therapy targeting an ultra-rare condition. The small sample size of 10 patients reflects the rarity of PNPO deficiency. However, the combination of Fast Track, Orphan Drug, and Rare Pediatric Disease designations creates a multi-layered regulatory pathway. The potential Priority Review Voucher adds a non-operational asset value contingent on NDA approval, distinct from the long-term commercial revenue of MC-1 itself.
Albert D. Friesen, President and Chief Executive Officer of Medicure, stated that the focus now turns to completing patient follow-up and advancing MC-1 toward a potential NDA submission. The company aims to bring the first approved therapy for PNPO deficiency to patients.
Historical Stock Returns for Poly Medicure
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -1.99% | -4.99% | -5.34% | +37.73% | -15.79% | +76.94% |
What is the anticipated timeline for Medicure to submit the New Drug Application (NDA) following the completion of patient follow-up?
How might the potential sale of the Priority Review Voucher impact Medicure's cash runway and ability to fund future pipeline developments?
Given the ultra-rare nature of PNPO deficiency, what pricing strategies or reimbursement pathways is Medicure likely to pursue to ensure commercial viability?
19
Access Market Heat-map & Insights 
Create, Save & Share your Screener 
Use 200+ Screening Filters 
